Mobile

A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016007-39

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to test the hypothesis that, for adult patients with T2DM treated with or without metformin, administration of LY2599506 significantly decreases the HbA1c from baseline to endpoint at 12 weeks as compared to glyburide.

Critère d'inclusion

  • Type 2 Diabetes

Liens